Ask about this productRelated genes to: EPRS antibody
- Gene:
- EPRS NIH gene
- Name:
- glutamyl-prolyl-tRNA synthetase
- Previous symbol:
- QPRS, QARS
- Synonyms:
- EARS, PARS, GLUPRORS
- Chromosome:
- 1q41
- Locus Type:
- gene with protein product
- Date approved:
- 1991-02-20
- Date modifiied:
- 2014-11-18
Related products to: EPRS antibody
Related articles to: EPRS antibody
- The clinical utility of PRS may be hindered by reliance on large, heterogeneous datasets for generation that dilute phenotypic specificity. Meanwhile, small, well-defined clinical cohorts (target) are ubiquitous but insufficient for PRS development. We propose an external-PRS framework (ePRS) borrowing from the transfer learning literature that integrates genetic evidence from target cohorts, incorporating continuous evidence measures and genetic correlation for robust predictions. Simulation indicates superior performance of ePRS across varying genetic correlations between the source and target phenotypes. ePRS refines an Idiopathic Generalized Epilepsy (IGE) PRS to improve differentiation between Juvenile Myoclonic Epilepsy (JME) and other IGE subtypes; and, leveraging a large attention deficit hyperactivity disorder GWAS, enhances predictions for impulsivity in JME. Finally, to address concerns about potential cross-platform artifacts, we trained and evaluated ePRS in the Canadian Cystic Fibrosis (CF) Gene Modifier Study cohort to predict CF-Related Diabetes using UK Biobank type 2 diabetes (T2D) summary statistics as the external source phenotype. ePRS continues to improve prediction accuracy in this single-cohort, harmonized-QC setting and offers more precise risk stratification and personalized care across complex traits. - Source: PubMed
Publication date: 2026/06/02
Lin YuChungBeier Christoph PatrickSobiskova ZuzanaKhalid HamandiStodberg TommyNg Ching ChingAndrade DanielleSyvertsen Marte RoaGardella ElenaOrsini AlessandroFong Choong YiZarubova JanaKajsov MichaelaLim Kheng SeangSelmer Kaja KristineIrelli Emanuele CerulliRubboli GuidoStriano Pasquale Pal Deb KStrug Lisa J - This umbrella review synthesises evidence from reviews on clinicians' documentation burden (DB) associated with electronic patient records (EPRs) in hospital and primary care settings. Guided by Donabedian's model (structure, process, outcomes), it maps causes of burden, barriers to real-time documentation, and technological solutions. Following the Joanna Briggs Institute (JBI) methodology, searches across six databases identified 2,739 records, with 166 under full-text review. Findings of this review will inform strategies to optimise real-time EPR use while minimising DB. - Source: PubMed
Rathnayake SarathKarunathilake NimanthaOdo ChinasaParisi VeronicaPink JoshuaTu JiadaZhao WenhongRandell Rebecca - Herpes simplex virus type 2 (HSV-2) is the principal cause of genital herpes, establishes lifelong latency with recurrent mucosal lesions, and facilitates acquisition of human immunodeficiency virus type 1 (HIV-1). Because current therapy still relies largely on nucleoside analogues and resistant isolates continue to emerge, alternative antiviral strategies are needed. In this study, halofuginone (HF), a halogenated analogue of the febrifugine scaffold, inhibited both wild-type and acyclovir-resistant HSV-2 in cultured cells at nanomolar concentrations. In a murine genital challenge model, topical administration before viral exposure reduced viral burden and alleviated local inflammatory responses. Pre-exposure experiments further showed that HF decreased the infectivity of extracellular HSV-2 particles and was associated with virion structural damage, whereas docking analysis suggested a possible interaction with glycoprotein D (gD). In parallel, partial reversal by L-proline supported a host component linked to inhibition of the prolyl-tRNA synthetase (ProRS) domain of glutamyl-prolyl-tRNA synthetase (EPRS). HF also suppressed HSV-2-induced activation of phosphoinositide 3-kinase (PI3K), protein kinase B (Akt), eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), and nuclear factor kappa B (NF-κB). Beyond HSV-2, HF remained active against herpes simplex virus type 1 (HSV-1) and C-C chemokine receptor type 5 (CCR5)-tropic HIV-1 and retained antiviral activity in an HSV-2/HIV-1 co-infection model. Overall, the data support a dual antiviral effect of HF, involving extracellular impairment of viral particles together with intracellular host-directed restriction, and warrant further evaluation of HF as a topical prevention candidate against HSV-2. - Source: PubMed
Publication date: 2026/05/14
Pan ZhizhiChen ZhuoHuang XiaolinLin YueningLi LinLiu ShuwenTan Suiyi - Polygenic risk score values vary with genetic ancestry due to differences in population-specific allele frequencies and linkage disequilibrium patterns. We present a framework to calibrate polygenic risk scores based on ancestral makeup. We propose the "expected polygenic risk score" or ePRS, defined as the expected value of a polygenic risk score based on one's global or local admixture patterns. We further define the "residual polygenic risk score" or rPRS as measuring the deviation of the polygenic risk score from the ePRS. The ePRS reflects the baseline ancestry-driven component of genetic risk, whereas the rPRS isolates an ancestry-agnostic measure of genetic liability. Simulation studies confirm that it suffices to adjust for ePRS to obtain nearly unbiased estimates of the polygenic risk score-outcome association without further adjusting for principal components. Using the TOPMed and the All of Us datasets, effect size estimates for the rPRS (adjusted for ePRS) are similar to those obtained from polygenic risk scores adjusting for genetic principal components. The ePRS framework can protect from population stratification in association analysis and provide an equitable strategy to interpret genetic risk across diverse populations. - Source: PubMed
Publication date: 2026/04/30
Huang Yu-JyunKurniansyah NuzululGoodman Matthew OSpitzer Brian WWang JiongmingStilp AdrienneLaurie Ceceliade Vries Paul SChen HanMin Yuan-ISims MarioPeloso Gina MGuo XiuqingBis Joshua CBrody Jennifer ARaffield Laura MSmith Jennifer AZhao WeiRotter Jerome IRich Stephen SRedline SusanFornage MyriamKaplan RobertFranceschini NoraLevy DanielMorrison Alanna CBoerwinkle EricSmith Nicholas LKooperberg CharlesPsaty Bruce MZöllner Sebastian Sofer Tamar - Electronic patient records (EPRs) have shown potential to improve health care delivery, coordination, and patient engagement. In Switzerland, the development of a national EPR is supported by the Confederation, while its deployment is carried out by the cantons through EPR communities. Since health policy and the organization of health systems are entrusted to cantonal governments, each of the 26 Swiss cantons must decide its strategy for the implementation and application of EPRs within its jurisdiction. The canton of Vaud has joined with other French-speaking cantons (Geneva, Valais, Fribourg, and Jura) in organizing the implementation of the EPR through the CARA association since 2018. By June 2025, approximately 32,350 individuals have opened an EPR (Dossier électronique du patient) through CARA, accounting for 28% of all EPRs opened nationwide at that time. - Source: PubMed
Publication date: 2026/04/21
Bastardot FrançoisLaRocco CatherineRobert MathildeSchoeb Veronika